Adam S. Grossman - May 15, 2025 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role
President and CEO, Director
Signature
/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact
Stock symbol
ADMA
Transactions as of
May 15, 2025
Transactions value $
-$327,450
Form type
4
Date filed
5/16/2025, 09:00 PM
Previous filing
Apr 16, 2025
Next filing
Jun 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Grossman Adam S President and CEO, Director C/O ADMA BIOLOGICS, INC., 465 STATE ROUTE 17, RAMSEY /s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact 2025-05-16 0001542517

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMA Common Stock Options Exercise $81K +15K +0.73% $5.40 2.07M May 15, 2025 Direct F1
transaction ADMA Common Stock Sale -$292K -15K -0.72% $19.45 2.06M May 15, 2025 Direct F1, F2
transaction ADMA Common Stock Sale -$117K -6K -0.29% $19.45 2.05M May 15, 2025 Direct F1, F2, F3, F4, F5
holding ADMA Common Stock 1.14M May 15, 2025 See Footnote F6
holding ADMA Common Stock 581K May 15, 2025 See Footnote F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADMA Stock Option (right to buy) Options Exercise $0 -15K -1.78% $0.00 826K May 15, 2025 Common Stock 15K $5.40 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.
F2 The price reported in Column 4 is the price at which the shares were sold.
F3 Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
F4 (continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
F5 (continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 1,017,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
F6 These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
F7 These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.
F8 The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.